FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Addington, J Cadenhead, K Cornblatt, B McGlashan, T Perkins, D Seidman, L Tsuang, M Walker, E Woods, S Mathalon, D Addington, J Saleem, M Cannon, T AF Addington, Jean Cadenhead, Kristin Cornblatt, Barbara McGlashan, Thomas Perkins, Diana Seidman, Larry Tsuang, Ming Walker, Elaine Woods, Scott Mathalon, Daniel Addington, Jack Saleem, Majid Cannon, Tyrone TI North American Prodrome Longitudinal Study (NAPLS 2): Overview and methods of predictors and mechanisms of conversion to psychosis SO EARLY INTERVENTION IN PSYCHIATRY LA English DT Meeting Abstract C1 [Addington, Jean; Addington, Jack; Saleem, Majid] Univ Calgary, Dept Psychiat, Hotchkiss Brain Inst, Calgary, AB, Canada. [Cadenhead, Kristin] Univ Calif San Diego, Dept Psychiat, San Diego, CA USA. [Cornblatt, Barbara; Tsuang, Ming] Zucker Hillside Hosp, Dept Psychiat, Long Isl City, NY USA. [McGlashan, Thomas; Woods, Scott] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Perkins, Diana] Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA. [Seidman, Larry] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Psychiat, Boston, MA 02215 USA. [Seidman, Larry] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Walker, Elaine] Emory Univ, Dept Psychol, Atlanta, GA 30322 USA. [Walker, Elaine] Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA. [Mathalon, Daniel] UCSF, Dept Psychiat, San Francisco, CA USA. [Cannon, Tyrone] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA. [Cannon, Tyrone] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1751-7885 J9 EARLY INTERV PSYCHIA JI Early Interv. Psychiatry PD OCT PY 2012 VL 6 SU 1 SI SI BP 126 EP 126 PG 1 WC Psychiatry SC Psychiatry GA 003AI UT WOS:000308580100480 ER PT J AU Stolzmann, P Schlett, CL Maurovich-Horvat, P Maehara, A Ma, SX Scheffel, H Engel, LC Karolyi, M Mintz, GS Hoffmann, U AF Stolzmann, Paul Schlett, Christopher L. Maurovich-Horvat, Pal Maehara, Akiko Ma, Shixin Scheffel, Hans Engel, Leif-Christopher Karolyi, Mihaly Mintz, Gary S. Hoffmann, Udo TI Variability and accuracy of coronary CT angiography including use of iterative reconstruction algorithms for plaque burden assessment as compared with intravascular ultrasound-an ex vivo study SO EUROPEAN RADIOLOGY LA English DT Article DE Intravascular ultrasound; Computed tomography coronary angiography; Coronary artery plaque burden; Measurement variability; Iterative image reconstruction algorithms ID 64-SLICE COMPUTED-TOMOGRAPHY; DUAL-SOURCE CT; ATHEROSCLEROTIC PLAQUES; ARTERY-DISEASE; REPRODUCIBILITY; QUANTIFICATION; STANDARD; MODEL AB To systematically assess inter-technique and inter-/intra-reader variability of coronary CT angiography (CTA) to measure plaque burden compared with intravascular ultrasound (IVUS) and to determine whether iterative reconstruction algorithms affect variability. IVUS and CTA data were acquired from nine human coronary arteries ex vivo. CT images were reconstructed using filtered back projection (FBPR) and iterative reconstruction algorithms: adaptive-statistical (ASIR) and model-based (MBIR). After co-registration of 284 cross-sections between IVUS and CTA, two readers manually delineated the cross-sectional plaque area in all images presented in random order. Average plaque burden by IVUS was 63.7 +/- 10.7% and correlated significantly with all CTA measurements (r = 0.45-0.52; P < 0.001), while CTA overestimated the burden by 10 +/- 10%. There were no significant differences among FBPR, ASIR and MBIR (P > 0.05). Increased overestimation was associated with smaller plaques, eccentricity and calcification (P < 0.001). Reproducibility of plaque burden by CTA and IVUS datasets was excellent with a low mean intra-/inter-reader variability of < 1/< 4% for CTA and < 0.5/< 1% for IVUS respectively (P < 0.05) with no significant difference between CT reconstruction algorithms (P > 0.05). In ex vivo coronary arteries, plaque burden by coronary CTA had extremely low inter-/intra-reader variability and correlated significantly with IVUS measurements. Accuracy as well as reader reliability were independent of CT image reconstruction algorithm. aEuro cent IVUS is deemed the gold standard in-vivo coronary plaque assessment aEuro cent But coronary CT angiography findings correlate strongly with IVUS results aEuro cent Coronary CT angiography now allows plaque quantification close to IVUS aEuro cent Iterative image reconstruction algorithms do not alter accuracy or reproducibility aEuro cent Plaque quantification is more challenging in smaller eccentric calcified lesions. C1 [Stolzmann, Paul; Schlett, Christopher L.; Maurovich-Horvat, Pal; Scheffel, Hans; Engel, Leif-Christopher; Karolyi, Mihaly; Hoffmann, Udo] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA. [Stolzmann, Paul; Schlett, Christopher L.; Maurovich-Horvat, Pal; Scheffel, Hans; Engel, Leif-Christopher; Karolyi, Mihaly; Hoffmann, Udo] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Stolzmann, Paul] Univ Zurich Hosp, Inst Diagnost & Intervent Radiol, CH-8091 Zurich, Switzerland. [Maehara, Akiko; Ma, Shixin; Mintz, Gary S.] Columbia Univ, Med Ctr, Cardiovasc Res Fdn, New York, NY USA. RP Hoffmann, U (reprint author), Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA. EM uhoffmann@partners.org OI Maurovich-Horvat, Pal/0000-0003-0885-736X FU GE Healthcare research grant FX This work was supported by a GE Healthcare research grant. NR 30 TC 12 Z9 12 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0938-7994 J9 EUR RADIOL JI Eur. Radiol. PD OCT PY 2012 VL 22 IS 10 BP 2067 EP 2075 DI 10.1007/s00330-012-2464-8 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 998KM UT WOS:000308237500002 PM 22622346 ER PT J AU Choudhury, AD Eeles, R Freedland, SJ Isaacs, WB Pomerantz, MM Schalken, JA Tammela, TLJ Visakorpi, T AF Choudhury, Atish D. Eeles, Rosalind Freedland, Stephen J. Isaacs, William B. Pomerantz, Mark M. Schalken, Jack A. Tammela, Teuvo L. J. Visakorpi, Tapio TI The Role of Genetic Markers in the Management of Prostate Cancer SO EUROPEAN UROLOGY LA English DT Review DE Genetic markers; Prostate cancer; GWAS; Genome-wide association study; Screening; Gene expression; Prognostic markers; Predictive markers ID GENOME-WIDE ASSOCIATION; ANDROGEN-DEPRIVATION THERAPY; LONG-RANGE INTERACTION; SUSCEPTIBILITY LOCI; POLY(ADP-RIBOSE) POLYMERASE; COLORECTAL-CANCER; URINARY SEDIMENTS; CLINICAL UTILITY; 8Q24 PROSTATE; CELL-GROWTH AB Context: Despite widespread screening for prostate cancer (PCa) and major advances in the treatment of metastatic disease, PCa remains the second most common cause of cancer death for men in the Western world. In addition, the use of prostate-specific antigen testing has led to the diagnosis of many potentially indolent cancers, and aggressive treatment of these cancers has caused significant morbidity without clinical benefit in many cases. The recent discoveries of inherited and acquired genetic markers associated with PCa initiation and progression provide an opportunity to apply these findings to guide clinical decision making. Objective: In this review, we discuss the potential use of genetic markers to better define groups of men at high risk of developing PCa, to improve screening techniques, to discriminate indolent versus aggressive disease, and to improve therapeutic strategies in patients with advanced disease. Evidence acquisition: PubMed-based literature searches and abstracts through January 2012 provided the basis for this literature review. We also examined secondary sources from reference lists of retrieved articles and data presented at recent congresses. Cited review articles are only from the years 2007-2012, favoring more recent discussions because of the rapidly changing field. Original research articles were curated based on favoring large sample sizes, independent validation, frequent citations, and basic science directly related to potentially clinically relevant prognostic or predictive markers. In addition, all authors on the manuscript evaluated and interpreted the data acquired. Evidence synthesis: We address the use of inherited genetic variants to assess risk of PCa development, risk of advanced disease, and duration of response to hormonal therapies. The potential for using urine measurements such as prostate cancer antigen 3 (PCA3) RNA and the transmembrane protease, serine 2 v-ets erythroblastosis virus E26 oncogene homolog (avian) (TMPRSS2-ERG) gene fusion to aid screening is discussed. Multiple groups have developed gene expression signatures from primary prostate tumors correlating with poor prognosis, and attempts to improve and standardize these signatures as diagnostic tests are presented. Massive sequencing efforts are underway to define important somatic genetic alterations (amplifications, deletions, point mutations, translocations) in PCa, and these alterations hold great promise as prognostic markers and for predicting response to therapy. We provide a rationale for assessing genetic markers in metastatic disease for guiding choice of therapy and for stratifying patients in clinical trials, and discuss challenges in clinical trial design incorporating the use of these markers. Conclusions: The use of genetic markers has the potential to aid disease screening, improve prognostic discrimination, and prediction of response to treatment. However, most markers have not been prospectively validated for providing useful prognostic or predictive information or improvement upon clinicopathologic parameters already in use. Significant efforts are underway to develop these research findings into clinically useful diagnostic tests in order to improve clinical decision making. (C) 2012 Published by Elsevier B.V. on behalf of European Association of Urology. C1 [Choudhury, Atish D.; Pomerantz, Mark M.] Dana Farber Canc Inst, Boston, MA 02215 USA. [Choudhury, Atish D.] Harvard & Massachusetts Inst Technol, Broad Inst, Cambridge, MA USA. [Eeles, Rosalind] Inst Canc Res, Oncogenet Team, Sutton, Surrey, England. [Eeles, Rosalind] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England. [Freedland, Stephen J.] Duke Univ, Sch Med, Durham VA Med Ctr, Durham, NC USA. [Isaacs, William B.] Johns Hopkins Med Inst, Brady Urol Inst, Baltimore, MD 21205 USA. [Schalken, Jack A.] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6525 ED Nijmegen, Netherlands. [Tammela, Teuvo L. J.] Univ Tampere, Dept Urol, FIN-33101 Tampere, Finland. [Tammela, Teuvo L. J.; Visakorpi, Tapio] Tampere Univ Hosp, Tampere, Finland. [Visakorpi, Tapio] Univ Tampere, Inst Biomed Technol, FIN-33101 Tampere, Finland. [Visakorpi, Tapio] Univ Tampere, BioMediTech, FIN-33101 Tampere, Finland. RP Pomerantz, MM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM mark_pomerantz@dfci.harvard.edu RI Schalken, Jack/B-1277-2014; OI Schalken, Jack/0000-0001-8274-7797; Eeles, Rosalind/0000-0002-3698-6241 FU US National Institutes of Health (NIH); Anne Huber Foster Fellowship; Prostate Cancer Foundation Young Investigator Award; US Department of Defense Physician Scientist Training Award; Cancer Research UK [C5047/A7357]; US NIH Cancer Post-GWAS initiative [1 U19 CA 148537-01]; European Commission [223175 (HEALTH-F2-2009-223175)]; US NIH National Institute for Health Research to the Biomedical Research Centre at The Institute of Cancer Research; Royal Marsden Foundation NHS Trust; Institute of Cancer Research; The Everyman Campaign; Prostate Action; Orchid Cancer Appeal; National Cancer Research Network UK; National Cancer Research Institute UK FX Dean A. Tripp certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Atish D. Choudhury is supported by a US National Institutes of Health (NIH) T-32 Training Grant, the Anne Huber Foster Fellowship, the Prostate Cancer Foundation Young Investigator Award and the US Department of Defense Physician Scientist Training Award. Rosalind Eeles is supported by Cancer Research UK Grant C5047/A7357, the US NIH Cancer Post-GWAS initiative grant number 1 U19 CA 148537-01 (GAME_ON initiative), The European Commission's Seventh Framework Programme grant agreement number 223175 (HEALTH-F2-2009-223175), and support from the US NIH National Institute for Health Research to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden Foundation NHS Trust, The Institute of Cancer Research and The Everyman Campaign, Prostate Action, The Orchid Cancer Appeal, The National Cancer Research Network UK, and The National Cancer Research Institute UK. Mark M. Pomerantz is supported by the Prostate Cancer Foundation Young Investigator Award. Tapio Visakorpi is supported by the Academy of Finland, the Cancer Society of Finland, the Reino Lahtikari Foundation, the Sigrid Juselius Foundation, European Union, TEKES, and the Medical Research Fund of Tampere University Hospital. NR 90 TC 55 Z9 55 U1 1 U2 26 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0302-2838 J9 EUR UROL JI Eur. Urol. PD OCT PY 2012 VL 62 IS 4 BP 577 EP 587 DI 10.1016/j.eururo.2012.05.054 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA 002UX UT WOS:000308563100008 PM 22695242 ER PT J AU Upadhyay, GA Mela, T Singh, JP AF Upadhyay, Gaurav A. Mela, Theofanie Singh, Jagmeet P. TI The burden of inappropriate shocks in young people and how to avoid them SO HEART LA English DT Article ID IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; RAPID VENTRICULAR-TACHYCARDIA; PROGNOSTIC IMPORTANCE; ATRIAL-FIBRILLATION; PRIMARY PREVENTION; HEART-FAILURE; ICD; TRIAL; THERAPY; MORTALITY C1 [Singh, Jagmeet P.] Harvard Univ, Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Med Sch,Heart Ctr, Boston, MA 02114 USA. RP Singh, JP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Med Sch,Heart Ctr, Gray Bldg 109,55 Fruit St, Boston, MA 02114 USA. EM jsingh@partners.org FU Heart Rhythm Society; St Jude Medical; Medtronic Inc; Boston Scientific Corp; Biotronik FX Dr Upadhyay received salary support from the 2011 Max Schaldach Fellowship in Cardiac Pacing and Electrophysiology of the Heart Rhythm Society. Dr Mela reports speaker's honoraria from Boston Scientific Corp, Medtronic Inc, and St Jude Medical. Dr Singh reports receiving research grants from St Jude Medical, Medtronic Inc, Boston Scientific Corp and Biotronik. He also serves on advisory boards or as a consultant for Boston Scientific Corp, St Jude Medical, Sorin Group, CardioInsight Inc, Respicardia Inc and Medtronic Inc. Finally, he has received speaker's honoraria from Medtronic Inc, Biotronik, Boston Scientific Corp, St Jude Medical and the Sorin Group. NR 21 TC 1 Z9 1 U1 0 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1355-6037 J9 HEART JI Heart PD OCT PY 2012 VL 98 IS 19 BP 1457 EP 1466 DI 10.1136/heartjnl-2012-301861 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 005KT UT WOS:000308750000013 PM 22965797 ER PT J AU Uppal, R Medarova, Z Farrar, CT Dai, GP Moore, A Caravan, P AF Uppal, Ritika Medarova, Zdravka Farrar, Christian T. Dai, Guangping Moore, Anna Caravan, Peter TI Molecular Imaging of Fibrin in a Breast Cancer Xenograft Mouse Model SO INVESTIGATIVE RADIOLOGY LA English DT Article DE fibrin; tumor stroma; EP-2104R; gadolinium; breast cancer ID TARGETED CONTRAST AGENT; TUMOR STROMA; EXTRACELLULAR-MATRIX; CORONARY-THROMBOSIS; PULMONARY EMBOLI; SWINE MODEL; MRI; EP-2104R; FEASIBILITY; METASTASIS AB Rationale and objectives: Fibrin deposition has been indicated within the stroma of a majority of solid tumors. Here we assess the feasibility of using the established fibrin-specific probe EP-2104R for noninvasive imaging of fibrin in the context of breast cancer. Methods: EP-2104R, untargeted gadopentetate dimeglumine (Gd-DTPA), and a newly synthesized nonfibrin binding control linear peptide (CLP) were compared using steady-state and dynamic contrast-enhanced magnetic resonance imaging in a breast cancer xenograft mouse model at 9.4 T. Results: EP-2104R transiently enhanced both tumor core and tumor periphery, but only the enhancement in the tumor periphery persisted even 90 minutes after EP-2104R administration. However, untargeted Gd-DTPA and CLP are not retained in the tumor periphery. The half-life of EP-2104R in the tumor periphery (103 +/- 18 minutes) is significantly longer (P < 0.05) than that of either Gd-DTPA (29.6 +/- 2.4 minutes) or CLP (42.4 +/- 1.5 minutes), but the rate of clearance is similar for all the 3 probes from the tumor core. The presence of high concentrations of fibrin in the tumor periphery was corroborated using immunohistochemistry with a fibrin-specific antibody. Conclusions: The persistent enhancement observed in the tumor periphery with EP-2104R is likely a result of its fibrin-specific binding rather than its size and demonstrates the feasibility of EP-2104R for molecular imaging of fibrin in tumor stroma. C1 Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. Harvard Univ, Sch Med, Charlestown, MA 02129 USA. RP Caravan, P (reprint author), Massachusetts Gen Hosp, Dept Radiol, 149 13th St,Suite 2301, Cambridge, MA 02129 USA. EM caravan@nmr.mgh.harvard.edu FU National Heart, Lung, and Blood Institute [R01HL109448]; National Institute of Biomedical Imaging and Bioengineering [R01EB009062]; National Center for Research Resources [P41RR14075, S10RR025563] FX This work was supported, in part, by award R01HL109448 from the National Heart, Lung, and Blood Institute; award R01EB009062 from the National Institute of Biomedical Imaging and Bioengineering; and awards P41RR14075 and S10RR025563 from the National Center for Research Resources. P. Caravan has equity in Factor 1A, LLC, the company that holds patent rights to EP-2104R. The other authors have no disclosures. NR 53 TC 16 Z9 17 U1 0 U2 22 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0020-9996 J9 INVEST RADIOL JI Invest. Radiol. PD OCT PY 2012 VL 47 IS 10 BP 553 EP 558 DI 10.1097/RLI.0b013e31825dddfb PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 007BV UT WOS:000308864700001 PM 22960948 ER PT J AU Hammond, SP Gagne, LS Stock, SR Marty, FM Gelman, RS Marasco, WA Poritz, MA Baden, LR AF Hammond, Sarah P. Gagne, Lisa S. Stock, Shannon R. Marty, Francisco M. Gelman, Rebecca S. Marasco, Wayne A. Poritz, Mark A. Baden, Lindsey R. TI Respiratory Virus Detection in Immunocompromised Patients with FilmArray Respiratory Panel Compared to Conventional Methods SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID CELL TRANSPLANT RECIPIENTS; HUMAN METAPNEUMOVIRUS INFECTION; POLYMERASE-CHAIN-REACTION; REAL-TIME PCR; PATHOGENS AB Respiratory virus infections cause significant morbidity and mortality in immunocompromised patients. Timely diagnosis is needed to provide optimal clinical care. Diagnostic tests routinely available at most institutions are limited by poor sensitivity and a slow turnaround time. We collected 90 respiratory samples from 87 immunocompromised patients (56 bronchoalveolar lavage and 34 nasopharyngeal aspirate samples) in order to compare the performance of routine respiratory virus testing available at our institution to the FilmArray respiratory panel assay, a novel diagnostic tool which utilizes multiplex PCR to test for 21 respiratory pathogens with a 1-h turnaround time. Samples with discordant results and 13 samples with concordant results underwent further verification testing by laboratory-developed real-time PCR. The FilmArray assay identified viral pathogens in more samples than did clinical testing (30/90 versus 16/90; McNemar P = 0.001). Most of the additional viral pathogens identified by the FilmArray respiratory panel assay that were confirmed by verification testing were pathogens not assessed by routine clinical tests, including rhinovirus/enterovirus, human metapneumovirus, and coronavirus. The FilmArray respiratory panel assay allowed for increased identification of respiratory viral pathogens in this cohort of immunocompromised patients. C1 [Hammond, Sarah P.; Gagne, Lisa S.; Marty, Francisco M.; Baden, Lindsey R.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA. [Hammond, Sarah P.; Stock, Shannon R.; Marty, Francisco M.; Gelman, Rebecca S.; Marasco, Wayne A.; Baden, Lindsey R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hammond, Sarah P.; Marty, Francisco M.; Gelman, Rebecca S.; Marasco, Wayne A.; Baden, Lindsey R.] Harvard Univ, Sch Med, Boston, MA USA. [Poritz, Mark A.] Idaho Technol Inc, Salt Lake City, UT USA. RP Hammond, SP (reprint author), Brigham & Womens Hosp, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA. EM shammond2@partners.org FU NIH/NIAID [1 R43 AI 082843-01]; Harvard Clinical and Translational Science Center from the NIH/NCRR [1 UL1 RR025758-01]; Harvard Center for AIDS Research from the NIH/NIAID [P30 AI060354-08] FX This work was supported by a Small Business Innovation Research grant, 1 R43 AI 082843-01, from the NIH/NIAID, by the Harvard Clinical and Translational Science Center, grant no. 1 UL1 RR025758-01 from the NIH/NCRR, and also by the Harvard Center for AIDS Research, grant P30 AI060354-08 from the NIH/NIAID. NR 14 TC 23 Z9 23 U1 0 U2 7 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2012 VL 50 IS 10 BP 3216 EP 3221 DI 10.1128/JCM.00538-12 PG 6 WC Microbiology SC Microbiology GA 007DY UT WOS:000308870200011 PM 22814461 ER PT J AU Weir, SK Fram, J Berg, G Kabbani, D Strymish, J Tang, M Fitzsimmons, D Brecher, SM Gupta, K AF Weir, Susan K. Fram, Julia Berg, Gretchen Kabbani, Dima Strymish, Judith Tang, Melody Fitzsimmons, Dianne Brecher, Stephen M. Gupta, Kalpana TI Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Isolates from Patients Newly Identified as Nasal Carriers SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID COAGULASE-NEGATIVE STAPHYLOCOCCI; HOSPITAL ADMISSION; MRSA INFECTION; PCR ASSAY; MUPIROCIN; COLONIZATION; CARRIAGE; USA300; RISK; DISCRIMINATION AB We aimed to determine whether additional molecular and microbiological evaluations of methicillin-resistant Staphylococcus aureus (MRSA) isolated from patients newly identified as nasal carriers were useful for control strategies and whether longitudinal testing during the same or repeat hospitalization changed MRSA status. Nasal swabs from patients positive by Xpert MRSA PCR and not known to be colonized in the previous year were cultured for S. aureus. Isolates were tested for resistance to a variety of antibiotics, including high-level mupirocin resistance (HLMR) and low-level mupirocin resistance (LLMR) and the presence of genes mecA and mupA and those for Panton-Valentine leukocidin (PVL), USA300, and USA400. Repeat nasal screens during the 6-month study were tested for continued presence of MRSA. Among 130 patients, cultures revealed MRSA in 85 (65.4%), methicillin-susceptible S. aureus in 19 (14.6%), and no growth in 26 (20%). MRSA isolates were USA300 positive in 13/85 (15.3%) and LLMR in 8/85 (9.4%) patients. No isolates were HLMR or mupA positive. mecA dropout was detected in 9/130 (6.9%) patients. The rate of subsequent MRSA infections in USA300-positive versus -negative patients was not different. MRSA nasal status remained concordant in 69/70 (98.6%) patients who had follow-up testing. The findings do not support expanding MRSA surveillance to include routine detection of genes for USA300, PVL, or mupA, all of which were either of low frequency or not significantly associated with MRSA infection risk in our population of newly identified nasal carriers. Repeat nasal screening for MRSA during the same or subsequent hospitalizations over 6 months could also be deferred, reducing costs associated with screening. C1 [Weir, Susan K.; Fram, Julia; Berg, Gretchen; Strymish, Judith; Gupta, Kalpana] VA Boston HCS, Dept Med, Boston, MA USA. [Weir, Susan K.; Kabbani, Dima; Brecher, Stephen M.; Gupta, Kalpana] Boston Univ, Sch Med, Boston, MA 02118 USA. [Strymish, Judith] Harvard Univ, Sch Med, Boston, MA USA. [Tang, Melody; Fitzsimmons, Dianne; Brecher, Stephen M.] VA Boston HCS, Dept Pathol, Boston, MA USA. [Tang, Melody; Fitzsimmons, Dianne; Brecher, Stephen M.] VA Boston HCS, Dept Lab Med, Boston, MA USA. RP Gupta, K (reprint author), VA Boston HCS, Dept Med, Boston, MA USA. EM Kalpana.gupta@va.gov FU National Center for Occupational Health and Infection Control, Office of Public Health and Environmental Hazards, Veterans Health Administration, Gainesville, FL FX This work was supported in part by the National Center for Occupational Health and Infection Control, Office of Public Health and Environmental Hazards, Veterans Health Administration, Gainesville, FL. NR 23 TC 5 Z9 5 U1 1 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD OCT PY 2012 VL 50 IS 10 BP 3283 EP 3286 DI 10.1128/JCM.01143-12 PG 4 WC Microbiology SC Microbiology GA 007DY UT WOS:000308870200021 PM 22837329 ER PT J AU Mestnik, MJ Feres, M Figueiredo, LC Soares, G Teles, RP Fermiano, D Duarte, PM Faveri, M AF Mestnik, Maria J. Feres, Magda Figueiredo, Luciene C. Soares, Geisla Teles, Ricardo P. Fermiano, Daiane Duarte, Poliana M. Faveri, Marcelo TI The effects of adjunctive metronidazole plus amoxicillin in the treatment of generalized aggressive periodontitis: a 1-year double-blinded, placebo-controlled, randomized clinical trial SO JOURNAL OF CLINICAL PERIODONTOLOGY LA English DT Article DE Amoxicillin; generalized aggressive periodontitis; metronidazole; periodontal disease; periodontal treatment; scaling and root planing ID ACTINOBACILLUS-ACTINOMYCETEMCOMITANS; TOOTH LOSS; MICROBIOLOGICAL BENEFITS; ANTIMICROBIAL THERAPY; DISEASE PROGRESSION; AMOXICILLIN/METRONIDAZOLE; MAINTENANCE; PARAMETERS; ATTACHMENT; DEPTH AB Aim To evaluate the clinical effects of the adjunctive use of metronidazole (MTZ) and amoxicillin (AMX) in the treatment of generalized aggressive periodontitis (GAgP). Methods Thirty subjects were randomly assigned to receive scaling and root planing (SRP) alone or combined with MTZ (400 similar to mg/TID) and AMX (500 similar to mg/TID) for 14 similar to days. Subjects were clinically monitored at baseline, 6 similar to months and 1 similar to year post-therapies. Results Both therapies led to a statistically significant improvement in all clinical parameters at 1 similar to year post-therapy (p similar to